Sign inJoin waitlistJoin the waitlist

Earle Burgess

Co-Leader · Wake Forest University Baptist Medical Center

Credentials: · · · ·

History

Wake Forest University Baptist Medical Center
Present
Wake Forest University Baptist Medical Center
Present

Hematology and Medical Oncology
Vanderbilt University Medical Center
2005–2008
Internal Medicine
Vanderbilt University Medical Center
2002–2005
Med Coll of Georgia
1998–2002
Wake Forest University
1994–1997

Research

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
New England Journal of Medicine · 2019 · 1,067 citations
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
New England Journal of Medicine · 2023 · 274 citations
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Journal of Clinical Oncology · 2023 · 187 citations

DR
Derek Raghavan
15 papers
Peter Clark
14 papers
Claud Grigg
13 papers
Arlene Siefker-Radtke
8 papers
CL
Chad Livasy
8 papers
Landon Brown
7 papers
Justin Matulay
6 papers
Kris Gaston
6 papers
Stephen Riggs
6 papers
AH
Aaron Hartman
5 papers
JK
James Kearns
5 papers
Mehmet Bilen
5 papers

Clinical trials

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Principal investigator · Active not recruiting · Phase 2
Wake Forest University Health Sciences
2017–2028
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Principal investigator · Terminated · Phase 2
Wake Forest University Health Sciences
2016–2019
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Site PI · Recruiting · Phase 3
Canadian Cancer Trials Group
2025–2031